Fig. 6

pro-SFTPB inhibits ADRM1-mediated PGK1 deubiquitination by binding to ADRM1. a-b Overexpression of pro-SFTPB reduces the interaction among ADRM1, hRpn2 and UCH37 in H1299 cells (a), while downregulation of pro-SFTPB expression increases it (b). Seventy-two hours after transfection, an anti-ADRM1 antibody was used to perform co-IP, and the indicated proteins were detected by Western blotting. c Predicted interaction residues between pro-SFTPB and ADRM1. d Co-IP analysis showing that overexpression of a mutant form of pro-SFTPB that binds to ADRM1 does not affect binding of ADRM1, hRpn2 and UCH37 in H1299 cells. Seventy-two hours after transfection, an anti-ADRM1 antibody was used to perform co-IP, and the indicated proteins were measured by Western blotting. e–f Overexpression of wild-type pro-SFTPB suppresses ADRM1-induced upregulation of PGK1 (e) and PGK1 deubiquitination (f), whereas mutant pro-SFTPB does not. Seventy-two hours after transfection, H1299 cells were subjected to Co-IP and Western blot analysis. WCL, whole cell lysate